Naomi Kresge Bloomberg

It was supposed to be a post-Covid-19 summer in Europe. Masks are gone in most places, and vacation season is in full swing as workers rush for the beaches and cities they missed in the two years marked by the pandemic.

The Omicron variant of Covid-19 may be less likely to land patients in the hospital than the Delta strain, according to a trio of studies of preliminary data.

A third dose of Moderna Inc.'s Covid-19 vaccine increased antibody levels against the omicron variant, results the company described as reassuring while it works on a shot tailored to the new strain.

The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters

Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec

Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.

The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.

BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.

Travel bans and other snap defenses that countries threw up against omicron, the new Covid-19 variant, are buying time for scientists to answer key questions that could prevent another wave of deaths.

Vaccines against Covid-19 are less effective against the delta variant, a large U.K. study showed in results that may fuel a push for booster shots for fully vaccinated people.

Vaccines against Covid-19 are less effective against the delta variant, a large U.K. study showed in results that may fuel a push for booster shots for fully vaccinated people.

One in two people hospitalized with COVID-19 develop another health complication, a UK study showed, in the broadest look yet at what happens to those sick enough to need inpatient treatment.

The Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.

Norway said Covid-19 vaccines may be too risky for the very old and terminally ill, the most cautious statement yet from a European health authority as countries assess the real-world side effects of the first shots to gain approval.

Now that Britain has become the first western country to approve a Covid-19 shot, the spotlight shifts to the high-stakes rollout. Vaccinating the country's roughly 67 million people won't happen overnight. The UK has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.

It was supposed to be a post-Covid-19 summer in Europe. Masks are gone in most places, and vacation season is in full swing as workers rush for the beaches and cities they missed in the two years marked by the pandemic.

The Omicron variant of Covid-19 may be less likely to land patients in the hospital than the Delta strain, according to a trio of studies of preliminary data.

A third dose of Moderna Inc.'s Covid-19 vaccine increased antibody levels against the omicron variant, results the company described as reassuring while it works on a shot tailored to the new strain.

The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters

Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec

Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.

The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.

BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.

Travel bans and other snap defenses that countries threw up against omicron, the new Covid-19 variant, are buying time for scientists to answer key questions that could prevent another wave of deaths.

Vaccines against Covid-19 are less effective against the delta variant, a large U.K. study showed in results that may fuel a push for booster shots for fully vaccinated people.

Vaccines against Covid-19 are less effective against the delta variant, a large U.K. study showed in results that may fuel a push for booster shots for fully vaccinated people.

One in two people hospitalized with COVID-19 develop another health complication, a UK study showed, in the broadest look yet at what happens to those sick enough to need inpatient treatment.

The Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.

Norway said Covid-19 vaccines may be too risky for the very old and terminally ill, the most cautious statement yet from a European health authority as countries assess the real-world side effects of the first shots to gain approval.

Now that Britain has become the first western country to approve a Covid-19 shot, the spotlight shifts to the high-stakes rollout. Vaccinating the country's roughly 67 million people won't happen overnight. The UK has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.